Soluble complement receptor type 1 inhibits complement activation induced by hemodialysis membranes in vitro  by Cheung, Alfred K. et al.
Kidney International, Vol. 46 (1994), pp. 1680—1687
Soluble complement receptor type 1 inhibits complement
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Soluble complement receptor type 1 inhibits complement activation
induced by hemodlalysis membranes in vitro. A variety of bioincompatible
events that occur during hemodialysis have been attributed to complement
activation. However, cause-effect relationships have been based primarily
on indirect evidence and the results of in vitro studies, because an
acceptable method for inhibiting complement activation during clinical
hemodialysis has been unavailable. Methods for inactivating complement
in vitro are available, but the most commonly used of these techniques
(heat inactivation and chelation of divalent cations) lack specificity. A
recombinant, soluble form of human complement receptor type I (sCR1)
has been developed recently and shown to inhibit complement activation
in vivo. Here, we report studies aimed at determining the effects of sCR1
on dialysis-induced complement activation and neutrophil degranulation.
In a concentration dependent fashion, sCR1 inhibited plasma complement
activation by cuprophan membrane in vitro. Using a maximally inhibitory
concentration (30 Wml), sCR1 blocked generation of C3a(desArg) by
cuprophan, cellulose acetate, and polymethylmethacrylate membranes by
90%, 84%, and 84%, respectively. In contrast, elastase release (a measure
of neutrophil degranulation) was inhibited by 70%, 70%, and 44%,
respectively, suggesting that dialysis-induced neutrophil activation is me-
diated in part by noncomplement dependent mechanisms. Both heat- and
EDTA-treatment of plasma abolished dialysis membrane-induced com-
plement activation, but these treatments also affected noncomplement
dependent components of the degranulation process. These observations
show that, compared with other commonly used methods for inhibiting
dialysis induced complement activation, 5CR1 is more specific. An addi-
tional advantage of sCR1 is its potential for use in the clinical setting.
During hemodialysis, plasma complement is activated by the
dialysis membrane. The complement system is the primary effec-
tor of humoral immunity, and activation of the complement
cascade generates a variety of proinfiammatory events [1, 2].
Complement activation can mediate cellular injury directly
through generation of the potentially cytolytic membrane attack
complex (C5b-9); however, most of the proinfiammatory events
associated with complement activation are mediated by stimula-
tion of cellular constituents of the immune system through
interactions with specific membrane receptors that bind comple-
ment activation products [3, 4]. Many of the untoward conse-
quences of hemodialysis have been attributed to membrane-
induced activation of complement. Evidence in support of a
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causal relationship, however, has been primarily indirect or based
on in vitro studies. For example, dialysis associated neutropenia [5,
6], promotion of interleukin-1f3 production by monocytes [7], and
release of 2-microglobulin from peripheral blood mononuclear
cells [8] have been attributed to the generation of C5a. While
experimental data support this interpretation, the evidence is
nonetheless indirect, because an acceptable method for specifi-
cally inhibiting complement activation during clinical hemodialy-
sis has been unavailable.
In vitro methods for inhibiting complement activation are
available. The most commonly used of these methods are heat
inactivation [9], chelation of divalent cations with EDTA [9, 10],
and the use of plasma with an isolated deficiency of a particular
complement component [11]. Heat treatment of plasma blocks
complement activation by destroying the functional activity of
heat labile components of both the classical (primarily C2) [12]
and the alternative (primarily factor B) [13] pathways. Both
pathways also require divalent cations (the classical pathway
requires both calcium and magnesium, while the alternative
pathway is magnesium dependent) [1, 2]. Thus, treatment of
plasma with EDTA also inhibits activation of both the classical
and alternative pathways. Heat treatment and chelation of diva-
lent cations are simple and effective methods for abolishing
complement activity, but both methods lack specificity. For exam-
ple, heating plasma for 30 minutes at 56°C may affect the function
of noncomplement proteins, and EDTA will affect any process
that is divalent cation dependent. The lack of specificity is
particularly problematic in experiments that analyze effects that
are not entirely complement dependent or are mediated indirectly
by complement activation. For example, cuprophan membrane-
induced neutrophil degranulation has been shown to be mediated
by both complement- and noncomplement-dependent mecha-
nisms [11]. Further, adhesion of cells to cuprophan membrane-
associated plasma proteins is an essential component of the
neutrophil degranulation process. Inasmuch as this binding is
divalent cation dependent [11, 14, 15], treatment of plasma with
EDTA prevents not only complement activation but also neutro-
phil adhesion. Thus, in this setting, it is impossible to determine if
a noncomplement plasma constituent contributes to the degran-
ulation process.
Because of its specificity, plasma with an isolated deficiency of
a particular complement component (such as C3-deficient
plasma) is useful for analyzing the effects of complement activa-
tion [11]. Interpretation of results is usually unambiguous if an
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effect that is lost when the deficient plasma is used is restored
when the deficient plasma is repleted with the missing comple-
ment protein. A major disadvantage of complement deficient
plasma is the lack of simplicity in the preparation and character-
ization of the reagent. Further, complement deficient plasma
cannot be used to assess the effects of complement activation
during clinical dialysis.
Complement receptor type I (CR1, CD35) is a 210 to 330 kDa
(depending on the allotype) type I integral membrane protein that
is present on erythrocytes, leukocytes, and on some nonhemato-
poietic tissues [3, 16, 17]. CR1 has distinct binding sites for both
C3b and C4b, and erythrocyte CR1 appears to play a critically
important role in the metabolism of immune complexes. CR1
regulates complement activation in two ways. First, it has decay
accelerating activity for the C3 and C5 convertases of both the
classical and the alternative pathways. Second, it serves as a
cofactor for the enzymatic degradation of C3b and C4b by factor
I. Unlike the activity of factor H, the plasma protein that regulates
the C3 and C5 convertases of the alternative pathway, the activity
of CR1 is not restricted on alternative pathway activator surfaces
[18]. This property of CR1 is of critical importance in the present
studies, because dialysis membranes are alternative pathway
activators [5, 6, 19]. A recombinant, soluble form of complement
receptor type 1 (5CR1) has become available recently [18, 20].
sCR1 is a truncated form of the membrane-associated protein that
lacks the hydrophobic transmembrane domain, making the re-
combinant protein soluble in aqueous solutions.
Because of its specificity and its potential for use in the clinical
setting, sCR1 appears to be an ideal reagent for use in experi-
ments aimed at delineating the role of complement in bioincom-
patible events associated with hemodialysis. As a first step toward
accomplishing these aims, the effects of sCR1 on complement
activation by dialysis membrane in vitro were analyzed.
Methods
Reagents
The following buffers and reagents were used: phosphate
buffered saline (PBS) contained 10 m sodium phosphate, pH 7.4
and 145 mM NaCl; HBSSIA, Hank's balanced saline solution
containing 0.5% (wt/vol) human serum albumin (Albuminar®,
Armour Pharmaceutical, Kankakee, Illinois, USA); disodium
ethylenediamine tetraacetate (EDTA; Sigma Chemical Co., St.
Louis, Missouri, USA); sodium heparin (LyphoMed, Rosemont,
Illinois, USA). sCR1 (BRL55730) was a kind gift of Dr. James
Levin (T Cell Sciences, Inc., Cambridge, Massachusetts, USA).
Plasma preparation and neutrophil isolation
Whole blood from healthy volunteers who had not taken
medication within 72 hours of the phlebotomy was anticoagulated
using 2 units of heparin/mI. Normal human plasma (NHP) was
prepared by centrifuging a portion of the blood and recovering the
supernate. For some experiments, EDTA (10 m final concen-
tration) was added to the plasma to chelate plasma divalent
cations (EDTA-treated plasma) [9, 10]. In some instances, the
plasma was heated for 30 minutes at 56°C to inactivate comple-
ment (heat-treated plasma) [9, 12, 13]. Heat-treated plasma was
centrifuged at 12,000 g for three minutes prior to use. All plasma
was diluted to 75% (vol/vol) with PBS and kept at 4°C prior to use
on the same day.
Additional heparin (5.5 U/mI) was added to the portion of
blood that was not used in the preparation of the plasma.
Neutrophils were isolated by dextran sedimentation, hypotonic
lysis of erythrocytes, and density gradient centrifugation (Ficoll-
Paque®, Pharmacia LKB Biotechnology, Piscataway, New Jersey,
USA) as previously described [21] and were resuspended in
HBSS/A. The cell preparations were >95% pure as determined
by microscopic examination of slides stained with Wright's re-
agent, and the cells were 99% viable as determined by tiypan blue
exclusion.
Plasma and neutrophils from a number of different donors were
used in these studies. On a given day, however, the same donor's
cells and autologous plasma were used in all parallel experiments.
Hemodialysis membranes
The following three different types of commercial hemodialysis
membranes in hollow fiber format were used in these studies:
cuprophan (CF1211, Travenol, Deerfield, Illinois, USA), cellulose
acetate (CA; CA9O, Baxter, Round Lake, Illinois, USA), and
polymethylmethacrylate (PMMA; Filtryzer B1-2.1U, Toray Indus-
tries, Tokyo, Japan). The membranes were cut into fragments of
—1 cm in length, and 4.7 mg of fibers were used in each individual
assay. Although the weight of the fibers were the same, the actual
surface area that was available for contact with the cells and
plasma might vary from one type of membrane to another because
of the asymmetric nature of some membranes and the differences
in their densities. Therefore, comparison of results among the
different types of membranes is inappropriate.
Concentration-dependent inhibition of complement activation
by sCR1
An aliquot of 125 pi of heparinized normal human plasma
(NHP) was incubated at 37°C with 4.7 mg of cuprophan mem-
brane and 3.3 X 10 neutrophils in the presence of either PBS or
PBS containing incremental concentrations of sCR1. The total
volume of the reaction mixture was 250 i.tl. After 120 minutes, 90
.d of the supernate was recovered, and an equal volume of
complement stablizing solution (Quidel, San Diego, California,
USA) and 4.5 id of 200 mtvi EDTA were added. The plasma
samples were stored at —70°C prior to being assayed for comple-
ment activation products as described below.
Effect of sCR1 on complement activation and neutrophil
degranulation induced by dialysis membranes
NHP (125 1.d) was incubated with 4.7 mg of cuprophan, CA, or
PMMA membranes and 3.3 x io isolated neutrophils in the
presence of either PBS or PBS containing 30 WmI of sCR1. The
total volume of the reaction mixture was 250 pA. In parallel
experiments, either heat- or EDTA-treated plasma was substi-
tuted for NHP, and the samples were incubated with neutrophils
and PBS (without sCR1) as described above. For each type of
plasma, an aliquot was treated with complement stablizing solu-
tion and EDTA as described above and immediately stored at
—70°C without incubation. These control samples were used to
determine the basal C3a(desg) concentrations in the plasma.
After 120 minutes, the supernate was recovered from the other
tubes and complement stablizing solution and EDTA were then
added. All plasma samples were stored at —70°C prior to being
assayed for C3a(de$g) and the neutrophil granular proteins,
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elastase and lactoferrin (see below). The increase in the concen-
tration of C3a(des.g) was calculated by subtracting the basal
concentration from that of the test samples.
Assays for complement activation
Complement activation was assessed by measuring the concen-
tration of C3a(desArg) in the supernate using a radioimmunoassay
(RIA) kit purchased from Amersham (Arlington Heights, Illinois,
USA). The standard curve for this assay is linear between 20 to
500 ng/ml. Generation of the membrane attack complex of
complement was determined by quantitating SC5b-9 using an
enzyme immunoassay (EIA) purchased from Quidel (San Diego,
California, USA). The standard curve is linear between 0 to 142
ng/ml.
ELISA for elastase and lactofemn
Elastase and lactoferrin were used as markers of release of
primaly and secondary neutrophil granules, respectively. Elastase
was measured using a two site enzyme-linked immunosorbent
assay (ELISA) as previously described [11]. The standard curve
for this assay is linear between 6 to 100 ng/ml. Lactoferrin was
measured using the same type of ELISA developed in our
laboratory. The IgG fraction of rabbit anti-human lactoferrin
(Sigma Chemical Co, St. Louis, Missouri, USA) was used as the
capture antibody, and the peroxidase-conjugated [22] IgG fraction
of anti-human lactoferrin (Cappel, Malvern, Pennsylvania, USA)
was used as the developing antibody. Human lactoferrin (Sigma)
was used to prepare the standards. The standard curve that was
developed was linear between 4 to 125 ng/ml of lactoferrin.
Data presentation and statistical analyses
All values are reported as the mean SEM. Differences in
concentrations of C3a(desg), elastase, and lactoferrin among the
four experimental groups in Figures 2 to 4 were first evaluated
using analysis of variance (ANOVA). Since there were statistically
significant differences (P < 0.001) among the groups as deter-
mined by ANOVA, Student's unpaired two-tailed t-test was used
to further analyze differences between groups [23].
Results
Inhibition of complement activation associated with cuprophan
membrane by sCR1
NHP was incubated with cuprophan membrane and neutrophils
in the presence of incremental concentrations of sCR1. Maximum
inhibition of C3 occurred at 30 tg/ml when generation of the
C3a(desArg) was reduced by —P90% (Fig. 1A). Maximum inhibition
of SC5b-9 required a lower concentration of sCR1. At 10 g/ml of
sCR1, no SC5b-9 could be detected in the plasma (Fig. 1B). These
results showed that sCR1 is effective in inhibiting complement
activation induced by dialysis membranes.
Effect of sCR1, heat-inactivation, and EDTA-treatment on
complement activation and neutrophil degranulation induced by
various types of dialysis membranes
The effects of sCR1 on complement activation and neutrophil
degranulation associated with various types of dialysis membranes
were assessed individually. Since both C3 and the terminal
components appeared to be maximally inhibited by 30 j.tg/ml of
sCR1 (Fig. 1 A and B), this concentration was used in all
sCR1, pg/mi
Fig. 1. Concentration-dependent inhibition of complement activation by
sCR1. NHP was incubated with cuprophan membrane and neutrophils in
the presence of either PBS or PBS containing incremental concentrations
of sCR1. The concentration of C3a(aes.g) (A) (N = 4 to 8 at each sCR1
concentration) and SC5b-9 (B) (N = 2at each sCR1 concentration except
for 30 g/ml where N = 5) in the plasma were subsequently quantitated
and presented as mean SEM. Maximum inhibition of C3 occurred at 30
tg/ml of sCR1, Inhibition at 30 ig/ml (N = 8) was greater than that
occurring at 10 jg/ml (N = 7; P < 0.001). Complete inhibition of
formation of the SC5b-9 complex occurred at 10 g/ml.
subsequent experiments. The effects of heat- and EDTA-treated
plasma on dialysis membrane-induced complement activation and
neutrophil degranulation were used for comparison with plasma
treated with sCR1.
Cuprophan membrane
sCR1 inhibited C3a(deg.g) generation associated with cu-
prophan membrane by 90% (Fig. 2A). These results are similar to
those presented in Figure IA. By comparison, EDTA inhibited
C3a(desg) generation by 95%, whereas heat treatment virtually
abolished C3 activation (Fig. 2A). When neutrophils were incu-
bated with cuprophan membrane and NHP containing sCR1,
elastase levels were reduced by 70% (Fig. 2B). Heat-treatment of
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plasma produced a similar degree (64%) of inhibition of neutro-
phil degranulation compared with sCR1 (P > 0.05). sCR1 and
heat-treatment decreased lactoferrin levels by 47% and 40%,
respectively (P> 0.05, sCR1 vs. heat-treatment; Fig. 2C). Increas-
ing the concentration of sCR1 to 70 .tgfml or 100 ig/ml did not
produce greater inhibition of the release of elastase and lacto-
ferrin compared to 30 .tg/m1 (data not shown). These studies show
that sCR1 and heat-treatment were less effective in inhibiting
elastase release from neutrophils than in inhibiting complement
activation and suggest that a noncomplement dependent pathway
participates in the degranulation process. Treatment of plasma
with EDTA nearly abolished the release of both elastase and
lactoferrin (Fig. 2 B and C). These results indicate that both the
complement and noncomplement pathways of degranulation are
divalent cation dependent.
CA membrane
sCR1 inhibited complement activation induced by cellulose
acetate by 84%, whereas heat-treatment virtually abolished
complement activation, and EDTA reduced generation of
C3a(desArg)by 93% (Fig. 3A). In the presence of sCR1, CA-
induced release of neutrophil elastase and lactoferrin were re-
duced by 70% and 67%, respectively (Fig. 3 B and C). In contrast,
heat-treatment reduced elastase and lactoferrin release by only
35% and 18%, respectively (Fig. 3 B and C). Release of elastase
and lactoferrin in the presence of heat-treated plasma was 2- and
2.5-fold greater than the release observed with sCR1-treated
plasma (P < 0.02 for elastase and P < 0.001 for lactoferrin,
heat-inactivated plasma vs. sCR1). These results suggest that,
when CA membranes are used, the activity of the noncomplement
dependent pathway of neutrophil degranulation is enhanced by
heat-treatment. As was the case with cuprophan membrane (Fig.
2 B and C), CA-induced neutrophil degranulation was blocked by
EDTA (Fig. 3 B and C), confirming that both the complement-
dependent and the heat-stable pathways of degranulation require
divalent cations.
PMMA membrane
Fig. 2. Inhibition of complement activation and neutrophil degranulation
induced by cuprophan membrane. Isolated neutrophils were incubated with
normal human plasma (NHP) and cuprophan membrane (Cu) in the
absence (NHP + Cu) or presence of 30 sg/ml of sCR1 (NHP + Cu ÷
sCR1). Subsequently, the supernate was assayed for C3a(deJg), elastase,
and lactoferrin. In parallel experiments, cells were incubated with heat-
inactivated plasma and cuprophan membrane (HIP + Cu), or with plasma
and cuprophan membrane in the presence of 10 mM EDTA (NHP + Cu
+ EDTA) (N = 9 for each group). Data are presented as mean SCM. (A)
Inhibition of C3 activation. sCR1 and EDTA inhibited C3a(desAr gener-
ation by 90% and 95%, respectively. Heat-treatment virtually abolished
C3 activation. * P< 0.001 vs. NHP + Cu; P< 0.001 vs. NHP + Cu + sCR1.
(B) Inhibition of elastase release. sCR1 and heat-treatment inhibited elastase
release by 70% and 64%, respectively, suggesting that 30 to 35% of the
release from primaly granules is mediated by mechanisms independent of
complement activation. EDTA nearly abolished elastase release, indicating
that both the complement and noncomplement mechanisms are dependent
on divalent cations. * P < 0.001 vs. NHP + Cu; ÷ P < 0.05 or lower vs. NHP
+ Cu + sCR1. (C) Inhibition of lactoferrin release. sCR1 and heat-treatment
reduced the concentration of lactoferrin (a measure of the release from
secondary granules) by 47% and 40%, respectively, whereas EDTA virtually
abolished lactoferrin release. These observations support the hypothesis that
a significant portion of the neutrophil degranulation induced by Cu and
NHP is mediated by a complement independent pathway that is divalent
cation dependent. * P < 0.002 or lower vs. NHP + Cu; + P< 0.05 or lower
vs. NHP + Cu + sCR1.
sCR1 also inhibited C3 activation induced by PMMA mem-
brane. The concentration of C3a(desArg) was reduced by 84% in
plasma containing sCR1 (Fig. 4A). Heat- and EDTA-treatment
were also effective inhibitors of complement activation induced by
PMMA (91% and 94% reduction in plasma C3a(desArg) genera-
tion, respectively; Fig. 4A). In contrast, sCR1 reduced plasma
elastase and lactoferrin concentrations by only 44% and 25%,
respectively, compared to plasma without sCR1 (these differences
were statistically significant, P < 0.005 and P < 0.05, respectively;
Fig. 4 B and C). These results demonstrate that, in contrast to
cuprophan, most of the neutrophil degranulation induced by
PMMA is mediated by a complement independent pathway. As
was the case for cellulose acetate (Fig. 3 B and C), heat-treated
plasma induced greater release of neutrophil granular proteins
than sCR1-treated plasma (P < 0.05 for both elastase and
lactoferrin, sCR1 vs. heat-treated plasma; Fig. 4 B and C). These
results suggest that the activity of the complement independent
pathway of neutrophil degranulation in the presence of PMMA is
also enhanced by heat-treatment. Both the complement and
noncomplement pathways of degranulation were blocked by
EDTA (Fig. 4 B and C).
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Fig. 3. Inhibition of complement activation and neutrophil degranulation
induced by cellulose acetate (CA) membrane. These experiments were
conducted in a manner analogous to those described in the legend to Fig.
2 except that CA membrane was substitued for cuprophan membrane (N
= 9 for each group). (A) Inhibition of C3 activation. sCR1 inhibited the
generation of C3a(derg) by 84%. Heat-treatment virtually abolished C3
activation. EDTA-treatment reduced C3a(desArg) generation by 93%. *
<0.005 or lower vs. NHP + CA; P< 0,005 or lower vs. NI-IF + CA +
sCR1. (B) Inhibition of elastase release. sCR1 inhibited elastase release by
70%, while the reduction caused by heat-treatment was only 35%. These
results suggest that when CA is used, the complement independent
mechanism of neutrophil degranulation is enhanced by heating. EDTA
virtually abolished neutrophil degranulation, showing that divalent cations
are required for both the complement-dependent and the complement-
independent pathways of neutrophil degranulation. * P < 0.05 or lower vs.
NH? + CA; +P < 0.02 or lower vs. NH? + CA + sCR1. (C) Inhibition
of lactoferrin release. sCR1 inhibited lactoferrin release induced by CA by
67%, while heat-treatment reduced the release by only 18%, These data
confinn that heat-treatment of plasma enhances the complement inde-
pendent mechanism of neutrophil degranulation. Inhibition by EDTA
demonstrates that degranulation is divalent cation dependent. * P <0.05
or lower vs. NH? + CA; + P < 0.001 vs. NHP + CA + sCR1.
Fig. 4. Inhibition of complement activation and neutrophil degranulation
induced by PMMA. These experiments were conducted in a manner
analogous to those described in the legend to Fig. 2 except that PMMA
was substituted for cuprophan membrane (N = 9 for each group). (A)
Inhibition of C3 activation. sCR1 reduced C3a(de*g) generation 84%.
Heat- and EDTA-treatment of plasma inhibited C3 activation by 91% and
94%, respectively. * P < 0.001 or lower vs. NHP + PMMA 1- P < 0.05
or lower vs. NHP + PMMA ÷ sCR1. (B) Inhibition of elastase release.
5CRI inhibited elastase release by 44%, demonstrating that the majority
of the elastase release induced by PMMA is mediated by noncomplement
mechanisms. Heat-treatment reduced elastase release by only 11%,
indicating that the noncomplement pathway of neutrophil degranulation is
enhanced by heating. EDTA inhibited elastase release by 90%, confirming
the requirement for divalent cations. * P < 0,05 or lower vs. N}IP +
PMMA; +P < 0.04 or lower vs. NHP + PMMA + sCR1. (C) Inhibition
of lactoferrin release. sCR1 reduced the concentration of lactoferrin by
only 25%, confirming that PMMA induced lactoferrin release from
neutrophils is primarily mediated by noncomplement-dependent mecha-
nisms. The decrement in lactoferrin release induced by heat treatment
(8%) was significantly less than that produced by sCR1, confirming that
the complement-independent pathway that mediates the release from
secondary granules is also augmented by heating plasma. Lactoferrin
release was reduced by 83% in the presence of EDTA. * P<0.05or lower
vs. NH? + PMMA; + P < 0.05 or lower vs. NHP + PMMA + sCR1.
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Discussion
The purpose of these studies was to determine the capacity of
sCR1 to inhibit complement activation induced by various hemo-
dialysis membranes. The results have shown that for cuprophan,
CA, and PMMA membranes, sCR1 reduced C3a generation by
90%, 84%, and 84%, respectively (Figs. 1A, 2A, 3A, 4A).
Cellulosic membranes activate complement via the alternative
pathway [5, 6, 19]. The physiological regulator of the alternative
pathway is the plasma protein, factor H. Factor H functions by
inhibiting the formation and accelerating the decay of the alter-
native pathway C3 convertase (C3bBb) [24, 25]. Surfaces that
activate the alternative pathway are distinguished from nonacti-
vator surfaces, because on activator surfaces, bound C3b has a
higher affinity for factor B than for factor H [26, 271. Under these
conditions, the formation and stability of the amplification con-
vertase, C3bBb, are favored. The biochemical properties of a
surface that determine its relative affinities for factor B and factor
H are incompletely understood; however, the carbohydrate moi-
ety appears to be an important factor [26—29]. Our previous
studies have demonstrated that cellulosic membranes have the
properties of an activator surface [19, 30, 31]. CR1 has the same
functional profile as factor H, but unlike factor H, the activity of
CR1 is not restricted on activator surfaces [18]. Based on these
observations, we hypothesized that sCR1 would inhibit comple-
ment activation induced by hemodialysis membranes. Maximum
inhibition of C3 activation on the three types of membrane ranged
from 84 to 90%. The lack of complete inhibition of C3 activation
suggests that a portion of the membrane bound C3b (the nonen-
zymatic subunit of the alternative pathway C3 convertase) may
not be accessible to sCR1. Nonetheless, sCR1 is an effective
inhibitor of dialysis membrane-induced complement activation.
sCR1 completely inhibited generation of the membrane attack
complex (Fig. 1B). Quantitation of SC5b-9 is a surrogate for
assessing CS activation. Because of stoichiometric requirements,
formation of a functional C5 convertase (C3bBbC3b) is less
efficient than formation of a functional C3 convertase (C3bBb)
[32}. Thus, the observation that sCR1 more effectively inhibits CS
activation than C3 activation (Fig. lB compared to 1A) was
anticipated.
Despite the effectiveness of sCR1 and heat-treatment in inhib-
iting C3 activation on cuprophan, elastase release was reduced by
only 64 to 70% (Fig. 2B). This degree of inhibition of elastase
release (a measure of release of the contents of the primary
granules) is similar to that observed in our previous study in which
substitution of normal plasma with C3-depleted plasma caused a
62% reduction in elastase release [11]. These results are consis-
tent with the hypothesis that dialysis membrane-induced neutro-
phil degranulation is mediated by both complement-dependent
and complement-independent mechanisms.
Both sCR1 and heat-treatment were less effective in reducing
lactoferrin release (a measure of release of the contents of the
secondary granules) than in reducing elastase release (Fig. 2C
compared to 2B). These results suggest that, while secretion of
secondary granules is also mediated by both complement-depen-
dent and complement-independent mechanisms, the noncomple-
ment mechanism is dominant. Consistent with this interpretation
are studies reporting that release of primary and secondary
granules is regulated by different mechanisms [33].
When cuprophan was used, the effects of sCR1 and heat-
treatment on neutrophil degranulation were similar (Fig. 2 B and
C). Based on these observations, it would seem reasonable to
conclude that heat-treatment of plasma is a simple and effective
way of determining the role of complement in neutrophil degran-
ulation induced by dialysis membranes. The effects of heat-
treatment of plasma on degranulation induced by CA (Fig. 3 B
and C) and PMMA (Fig. 4 B and C), however, invalidate this
conclusion. In contrast to cuprophan, degranulation induced by
heat-treated plasma in the presence of CA and PMMA was
significantly greater than that observed with sCR1. This difference
was almost 2.5-fold in the case of lactoferrin release induced by
CA (Fig. 3C). The addition of sCR1 to heat-treated plasma and
neutrophils did not decrease the release of elastase and lacto-
ferrin, compared to incubation of cells with heat-treated plasma
alone (data not shown), confirming that the complement-depen-
dent component of neutrophil degranulation had been effectively
abolished by heat-treatment of plasma. Together, these data
suggest that heating plasma enhances the activity of the non-
complement pathway of degranulation in the presence of these
membranes. Inasmuch as the plasma factor(s) involved in the
complement-independent pathway has not been identified, the
mechanism by which heat-treatment enhances the degranulation
process remains speculative.
Clinical hemodialysis using PMMA membrane is associated
with higher plasma elastase levels than dialysis using cuprophan
membrane even though PMMA induces less complement activa-
tion [34, 35]. The explanation for this observation has not been
apparent, however, Schaefer, Heidland and HOrl [36] have pos-
tulated that shearing of the cells at the blood-dialysis membrane
interphase contributes to the degranulation induced by PMMA.
Our present studies showed that inhibition of complement acti-
vation by PMMA membrane using sCR1 produced only a 44%
reduction in elastase release (Fig. 4B), and inhibition of lacto-
ferrin was even less (25%, Fig. 4C). These results show that
neutrophil degranulation induced by PMMA is mediated primar-
ily by a complement-independent mechanism. Thus, our experi-
ments suggest a plausible explanation for why the plasma elastase
levels are high during clinical dialysis using PMMA despite the
relatively low complement activation.
Treatment of plasma with EDTA is a simple, effective method
of inhibiting complement activation; however, our studies dem-
onstrate that chelation of divalent cations affects processes other
than complement activation. Neutrophil degranulation induced by
cuprophan membrane is dependent on adhesion of the cells to the
membrane. This process is mediated primarily by the f32-integrin,
CD11b/CD18 [11], and adhesion of CD11b/CD18 to its ligands
(both complement and noncomplement proteins) is divalent
cation dependent [14, 15]. Thus, EDTA inhibits neutrophil de-
granulation independent of its effect on complement activation
(Figs. 2, 3, and 4), and is therefore not a satisfactory method of
assessing the consequences of complement activation.
By making comparisons among various experimental groups
using the same type of membrane, we were able to analyze the
effects sCR1, and heat- and EDTA-treatment on complement
activation and neutrophil degranulation by each membrane. Com-
parisons of complement activation and neutrophil degranulation
among the different types of membranes is problematic, since the
actual surface area of the membranes available for contact with
plasma and cells may be very different. In this system, in which
hollow fiber fragments were used to maximize the surface area,
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both the blood side and the dialysate side of the membrane were
exposed. Asymmetry makes determination of the actual total
surface area of the membrane difficult [37]. Additionally, the
membranes were standardized by weight (4.7mg in each tube) but
not by nominal or actual surface area. Thus, comparisons of
complement activation and neutrophil degranulation among the
different membranes should be avoided.
In addition to granular proteins, reactive oxygen species are
released from neutrophils during hemodialysis [38]. In coopera-
tion with granular proteases or by itself, reactive oxygen species
can injure surrounding proteins [39]. Modification of plasma
lipids suggestive of free radical activity has also been reported
during clinical dialysis [40]. While activated complement frag-
ments, such as C5a [41] and C3b/iC3b [42], have been shown to
induce oxidative burst by neutrophils in vitro, to which extent
complement activation contributes to this event during clinical
dialysis remains to be determined.
These studies have demonstrated that sCR1 is an effective,
specific inhibitor of complement activation induced by dialysis
membranes. Considerable resources have been used in an attempt
to improve dialysis membrane biocompatibility by reducing the
complement activating potential. Direct evidence showing that
reduction of complement activation is clinically beneficial, how-
ever, is lacking. Our studies support the hypothesis that sCR1 can
be used to evaluate the consequences of complement activation
during clinical hemodialysis.
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